---
title: "Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says"
date: 2025-07-21T15:12:05+08:00
categories: ["finance"]
tags: ["NMS:SRPT"]
summary: "Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, accord"
source_url: "https://www.bloomberg.com/news/articles/2025-07-21/sarepta-is-worth-0-amid-unwinnable-fda-fight-analyst-says"
---

Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, according to analysts at HC Wainwright &amp; Co. LLC.

---

*来源: [原文链接](https://www.bloomberg.com/news/articles/2025-07-21/sarepta-is-worth-0-amid-unwinnable-fda-fight-analyst-says)*
